3M Submits Aldara For Actinic Keratosis, Plans Carcinoma Filing Mid-Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
3M could gain two new indications for its topical immune response modifier Aldara in 2004, with a recent submission for actinic keratosis and a filing for basal cell carcinoma planned for this summer.